NRSN logo

NeuroSense Therapeutics (NRSN)

Profile

Full Name

NeuroSense Therapeutics Ltd.

Ticker Symbol

NRSN

Exchange

NASDAQ

Sector

Healthcare

Industry

Biotechnology

Country

Israel

IPO

December 9, 2021

Indexes

Not included

Website

http://www.neurosense-tx.com

Employees

17

Key Details

Price

$1.06(-1.85%)

Market cap

Last Dividend

-

TTM Dividend yield

-

Annual revenue

-

Annual EPS

-$0.54(+27.03% YoY)

PE ratio

-

Next earnings date

N/A

Next ex-dividend date

N/A

Next split date

N/A

Price

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Current Price

$1.06
NRSN price is $1.06

30-Day Relative Volume

0.71
NRSN 30-day relative volume is 0.71

Price Performance

Price Most recent change

-1.85%
NRSN price was down -1.85% on Apr 15, 2025

Price YTD change

-11.67%
NRSN price is down -11.67% since January 1st

Price 1-year change

-30.72%
NRSN price is down -30.72% year-on-year

Price 3-year change

-47.52%
NRSN price is down -47.52% over the past 3 years

Price Range

Price All-time high

$8.18
NRSN price is currently -87.04% below its historical high of $8.18

Price 3-year low

$0.40
NRSN price is currently +165.00% above its 3-year low

Capitalization

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Market cap

Market cap

$24.62M
NRSN market capitalization is $24.62 million

Market cap 3-year change

+11.39%
NRSN market capitalization is up +11.39% over the past 3 years

Market cap All-time high

$68.18M
NRSN market capitalization is currently -63.88% below its historical high of $68.18 million

Market cap sector rank

29.44%
NRSN market capitalization is higher than 29.44% of companies in Healthcare sector

Shares Outstanding

Shares Outstanding 1-Year Change

+48.88%
NRSN shares outstanding is up +48.88% year-on-year

Shares Outstanding 3-Year Change

+112.26%
NRSN shares outstanding is up +112.26% over the past 3 years

Technical Indicators

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Beta

0.31
NRSN beta is 0.31

200-day SMA

$1.06
NRSN price is currently -0.33% below its 200-day simple moving average

50-day SMA

$1.08
NRSN price is currently -1.90% below its 50-day simple moving average

RSI

53.98
NRSN 14-day relative strength index is 53.98

Volume

0.71
NRSN 30-day relative volume is 0.71

ATR

$0.10
NRSN average true range is $0.10

10-day Historical Volatility

50.32%
NRSN 10-day historical volatility is 50.32%

Dividend

Income Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Revenue

-
NRSN annual revenue value is unknown

Revenue Analysts estimate

-
NRSN annual revenue consensus analysts' forecast is unknown

Revenue 1-year change

-
NRSN annual revenue 1-year change is unknown

Revenue Sector rank

-
NRSN annual revenue is unknown

EPS

EPS

-$0.54
NRSN annual earnings per share is -$0.54

EPS Analysts estimate

-$0.56
NRSN annual earnings per share is currently -2.70% lower than the consensus analysts' forecast

EPS 1-year change

+27.03%
NRSN annual earnings per share is up +27.03% year-on-year

EPS Sector rank

67.52%
NRSN annual earnings per share is higher than 67.52% of companies in Healthcare sector

Profit

Gross profit

-
NRSN annual gross profit value is unknown

Gross margin

-
NRSN annual gross profit margin value is unknown

Operating profit

-$9.90M
NRSN annual operating income is -$9.90 million

Operating margin

-
NRSN annual operating profit margin value is unknown

Net income

-$10.21M
NRSN annual net profit is -$10.21 million

Net margin

-
NRSN annual net profit margin value is unknown

Expenses

Total expenses

$9.90M
NRSN annual total expenses is $9.90 million

Operating expenses

$9.90M
NRSN annual total operating expenses is $9.90 million

Cost of goods sold

-
NRSN annual cost of goods sold value is unknown

Selling, general & administrative expenses

$4.20M
NRSN annual SGA is $4.20 million

Depreciation and amortization

$22.00K
NRSN annual depreciation & amortization is $22.00 thousand

Interest expense

-
NRSN annual interest expense value is unknown

Income tax

-
NRSN annual income tax value is unknown

EBIT & EBITDA

EBIT

-$9.90M
NRSN annual earnings before interest & taxes is -$9.90 million

EBITDA

-$9.88M
NRSN annual EBITDA is -$9.88 million

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Total assets

$4.58M
NRSN annual total assets is $4.58 million

Non current assets

$173.00K
NRSN annual long term assets is $173.00 thousand

Current assets

$4.40M
NRSN annual total current assets is $4.40 million

Cash and cash equivalents

$3.38M
NRSN annual cash & cash equivalents is $3.38 million

Accounts receivable

-
NRSN annual accounts receivable value is unknown

Inventory

-
NRSN annual inventory value is unknown

Liabilities

Total liabilities

$1.99M
NRSN annual total liabilities is $1.99 million

Long term liabilities

$0.00
NRSN annual total long term liabilities is $0.00

Current liabilities

$1.99M
NRSN annual total current liabilities is $1.99 million

Accounts payable

$1.16M
NRSN annual accounts payable is $1.16 million

Debt

Total debt

$73.00K
NRSN annual total debt is $73.00 thousand

Total debt 1-year change

-48.59%
NRSN annual total debt is down -48.59% year-on-year

Long term debt

$0.00
NRSN annual long term debt is $0.00

Short term debt

$73.00K
NRSN annual short term debt is $73.00 thousand

Equity & Capital

Shareholders equity

$2.58M
NRSN annual stockholders equity is $2.58 million

Book value

$2.58M
NRSN annual book value is $2.58 million

Retained earnings

-$36.66M
NRSN annual retained earnings is -$36.66 million

Working capital

$2.41M
NRSN annual working capital is $2.41 million

Cash Flow Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Cash from operations

-$10.13M
NRSN annual cash flow from operations is -$10.13 million

Cash from operations 1-year change

-21.32%
NRSN annual cash flow from operations is down -21.32% year-on-year

Cash from investing

$1000.00
NRSN annual cash flow from investing activities is $1000.00

Cash from investing 1-year change

-99.97%
NRSN annual cash flow from investing activities is down -99.97% year-on-year

Cash from financing

$10.91M
NRSN annual cash flow from financing activities is $10.91 million

Cash from financing 1-year change

+174.54%
NRSN annual cash flow from financing activities is up +174.54% year-on-year

CAPEX

CAPEX

-
NRSN annual capital expenditures value is unknown

CAPEX 1-year change

-
NRSN annual capital expenditures 1-year change is unknown

Free Cash Flow

Free cash flow

-$10.14M
NRSN annual free cash flow is -$10.14 million

Free cash flow 1-year change

-20.94%
NRSN annual free cash flow is down -20.94% year-on-year

Profitability Ratios

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Margins

Gross margin

-
NRSN annual gross profit margin value is unknown

Operating margin

-
NRSN annual operating profit margin value is unknown

Net margin

-
NRSN annual net profit margin value is unknown

ROA & ROE

ROA

-223.17%
NRSN annual return on assets is -223.17%

ROE

-395.28%
NRSN annual return on equity is -395.28%

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PE ratio

-
NRSN price to earnings ratio value is unknown

PE ratio Sector rank

-
NRSN price to earnings ratio is unknown

PB Ratio

PB ratio

9.53
NRSN price to book ratio is 9.53

PB ratio Sector rank

91.77%
NRSN price to book ratio is higher than 91.77% of companies in Healthcare sector

PS Ratio

PS ratio

-
NRSN price to sales ratio value is unknown

PS ratio Sector rank

-
NRSN price to sales ratio is unknown

Enterprise value

Enterprise value

$21.32M
NRSN enterprise value is $21.32 million

Enterprise value Sector rank

32.18%
NRSN enterprise value is higher than 32.18% of companies in Healthcare sector

EV/EBITDA

EV/EBITDA

-2.15
NRSN EV/EBITDA is -2.15

EV/EBITDA Sector rank

30.64%
NRSN EV/EBITDA is higher than 30.64% of companies in Healthcare sector

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Current ratio

2.21
NRSN annual current ratio is 2.21

Quick ratio

-
NRSN annual quick ratio value is unknown

Leverage

Debt to equity

0.03
NRSN annual debt to equity ratio is 0.03

Interest coverage ratio

-
NRSN annual interest coverage ratio value is unknown

Risk & Stability

Piotroski F-Score

-
NRSN piotroski f-score value is unknown

Altman Z-Score

-
NRSN altman z-score value is unknown

Analyst ratings

Recent major analysts updates

Dec 16, 24 Maxim Group
Hold

Institutional Ownership

Similar stocks

GBIO logo
Generation Bio Co (GBIO)
QTTB logo
Q32 Bio (QTTB)
DOMH logo
Dominari Holdings (DOMH)
LEXX logo
Lexaria Bioscience (LEXX)
POCI logo
Precision Optics (POCI)
Aspire BioPharma (ASBP)
ANVS logo
Annovis Bio (ANVS)
CGTX logo
Cognition Therapeutics (CGTX)
SXTC logo
China SXT Pharmaceuticals (SXTC)
  • What is the ticker symbol for NeuroSense Therapeutics?
  • Does NeuroSense Therapeutics pay dividends?
  • What sector is NeuroSense Therapeutics in?
  • What industry is NeuroSense Therapeutics in?
  • What country is NeuroSense Therapeutics based in?
  • When did NeuroSense Therapeutics go public?
  • Is NeuroSense Therapeutics in the S&P 500?
  • Is NeuroSense Therapeutics in the NASDAQ 100?
  • Is NeuroSense Therapeutics in the Dow Jones?
  • When was NeuroSense Therapeutics's last earnings report?
  • When does NeuroSense Therapeutics report earnings?
  • Should I buy NeuroSense Therapeutics stock now?

What is the ticker symbol for NeuroSense Therapeutics?

The ticker symbol for NeuroSense Therapeutics is NASDAQ:NRSN

Does NeuroSense Therapeutics pay dividends?

No, NeuroSense Therapeutics does not pay dividends

What sector is NeuroSense Therapeutics in?

NeuroSense Therapeutics is in the Healthcare sector

What industry is NeuroSense Therapeutics in?

NeuroSense Therapeutics is in the Biotechnology industry

What country is NeuroSense Therapeutics based in?

NeuroSense Therapeutics is headquartered in Israel

When did NeuroSense Therapeutics go public?

NeuroSense Therapeutics's initial public offering (IPO) was on December 9, 2021

Is NeuroSense Therapeutics in the S&P 500?

No, NeuroSense Therapeutics is not included in the S&P 500 index

Is NeuroSense Therapeutics in the NASDAQ 100?

No, NeuroSense Therapeutics is not included in the NASDAQ 100 index

Is NeuroSense Therapeutics in the Dow Jones?

No, NeuroSense Therapeutics is not included in the Dow Jones index

When was NeuroSense Therapeutics's last earnings report?

NeuroSense Therapeutics's most recent earnings report was on Mar 22, 2023

When does NeuroSense Therapeutics report earnings?

The date for NeuroSense Therapeutics's next earnings report has not been announced yet

Should I buy NeuroSense Therapeutics stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions
On this page